179 related articles for article (PubMed ID: 10575057)
1. Beyond lipids - the role of the endothelium in coronary artery disease.
Aengevaeren WR
Atherosclerosis; 1999 Sep; 147 Suppl 1():S11-6. PubMed ID: 10575057
[TBL] [Abstract][Full Text] [Related]
2. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease.
Ling MC; Ruddy TD; deKemp RA; Ukkonen H; Duchesne L; Higginson L; Williams KA; McPherson R; Beanlands R
Am Heart J; 2005 Jun; 149(6):1137. PubMed ID: 15976803
[TBL] [Abstract][Full Text] [Related]
3. Effect of mild endurance exercise training and pravastatin on peripheral vasodilatation of forearm resistance vessels in patients with coronary artery disease.
Allemann Y; Vetter C; Kartal N; Eyer S; Stengel SM; Saner H; Hess OM
Eur J Cardiovasc Prev Rehabil; 2005 Aug; 12(4):332-40. PubMed ID: 16079640
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events.
Arntz HR
Atherosclerosis; 1999 Sep; 147 Suppl 1():S17-21. PubMed ID: 10575058
[TBL] [Abstract][Full Text] [Related]
5. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase.
Chen H; Ren JY; Xing Y; Zhang WL; Liu X; Wu P; Wang RJ; Luo Y
Int J Cardiol; 2009 Jan; 131(3):313-20. PubMed ID: 18221806
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk factor profiles and endothelial function in coronary artery disease patients treated with statins.
Okura Y; Takao M; Zhang B; Nakashima Y; Saku K
Hypertens Res; 2004 Oct; 27(10):723-9. PubMed ID: 15785007
[TBL] [Abstract][Full Text] [Related]
7. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
[TBL] [Abstract][Full Text] [Related]
8. Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
Takase S; Matoba T; Nakashiro S; Mukai Y; Inoue S; Oi K; Higo T; Katsuki S; Takemoto M; Suematsu N; Eshima K; Miyata K; Yamamoto M; Usui M; Sadamatsu K; Satoh S; Kadokami T; Hironaga K; Ichi I; Todaka K; Kishimoto J; Egashira K; Sunagawa K
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):350-358. PubMed ID: 27932353
[TBL] [Abstract][Full Text] [Related]
9. Beyond lipid lowering: the role of statins in vascular protection.
Liao JK
Int J Cardiol; 2002 Nov; 86(1):5-18. PubMed ID: 12243846
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
12. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
[TBL] [Abstract][Full Text] [Related]
13. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
Cohen JD; Drury JH; Ostdiek J; Finn J; Babu BR; Flaker G; Belew K; Donohue T; Labovitz A
Am Heart J; 2000 Apr; 139(4):734-8. PubMed ID: 10740160
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
Sebestjen M; Boh M; Keber I
Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
[TBL] [Abstract][Full Text] [Related]
15. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
16. Effect of Aggressive lipid-lowering treatment with Rosuvastatin on vascular endoTHelium function: evaluation of vascular endothelium function (EARTH study).
Takayama T; Hiro T; Yoda S; Fukamachi D; Haruta H; Kogo T; Mineki T; Murata H; Oshima T; Hirayama A
Heart Vessels; 2018 Jun; 33(6):590-594. PubMed ID: 29209775
[TBL] [Abstract][Full Text] [Related]
17. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy.
Fichtlscherer S; Schmidt-Lucke C; Bojunga S; Rössig L; Heeschen C; Dimmeler S; Zeiher AM
Eur Heart J; 2006 May; 27(10):1182-90. PubMed ID: 16621868
[TBL] [Abstract][Full Text] [Related]
19. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
20. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
